NovaBridge Biosciences

NBP · NASDAQ

$1.43+$0.125 (+9.62%)TodayMarket closed ·
Prev close $1.30

Latest news

  • News

    NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia

  • Press releaseGlobe Newswire

    Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia

  • News

    Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop

  • Press releasePRNewswire

    Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China

  • Press releaseGlobe Newswire

    Visara Expands Ophthalmology Pipeline with Exclusive License for Investigational Nerve Growth Factor Therapy for Neurotrophic Keratitis

  • Press releaseGlobe Newswire

    NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    NovaBridge Biosciences H1 2026 Earnings Call: Complete Transcript

  • Press releaseGlobe Newswire

    NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director

  • Press releaseGlobe Newswire

    NovaBridge Biosciences to Participate in September Investor Conferences

  • Press releaseGlobe Newswire

    NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

  • Press releaseGlobe Newswire

    NovaBridge Biosciences to Hold Annual General Meeting on September 8, 2026

  • Press releaseGlobe Newswire

    NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference

  • Press releaseGlobe Newswire

    NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

  • Press releaseGlobe Newswire

    NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

  • Press releaseGlobe Newswire

    NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026

  • Press releaseGlobe Newswire

    NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.